FindTrial
Sign In

Clincal study of umbilical cord-derived mesenchymal stem cells in the graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Clincal study of umbilical cord-derived mesenchymal stem cells in the graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-17011480
Enrollment
Unknown
Registered
2017-05-24
Start date
2017-05-15
Completion date
Unknown
Last updated
2017-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

graft-versus-host disease

Interventions

MSCs infusion group:infusion umbilical cord-derived MSCs 1*10^6/kg per one week, total 4-6 times

Sponsors

Tianjin First Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Allo-HSCT patients occured GVHD; 2. Aged between 14 to 65 years; 3. KPS score > 60; 4. No serious organ dysfunction; 5. Expected survival > 1 months.

Exclusion criteria

Exclusion criteria: 1. Have serious organ dysfunction; 2. Combined with other cancer need treatment; 3. Presence of clinical signs of brain dysfuntion or severe mental illness can not comply with the study protocol; 4. Can not scheduled follow-up; 5. Can not guarantee the completion of the treatment plan and the necessary follow-up observation.

Design outcomes

Primary

MeasureTime frame
GVHD;—

Secondary

MeasureTime frame
overall survival;Relapse-free survival;—

Countries

China

Contacts

Public ContactZhao Mingfeng

Tianjin First Central Hospital

mingfengzhao@sina.com+86 13752640369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026